NASDAQ:EVOK

Delisted

Evoke Pharma Stock News

Healthcare > Drug Manufacturers - Specialty & Generic

Buy EVOK

*Your capital is at risk

$11.00

+0 (+0%)

At Close: Mar 16, 2026

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

12:00am, Saturday, 30'th Mar 2019

Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

12:00am, Friday, 29'th Mar 2019

71 Biggest Movers From Yesterday

12:00am, Friday, 15'th Mar 2019

Evoke Pharma Reports Submission To FDA Review Letter For Gimoti New Drug Application

12:00am, Thursday, 14'th Mar 2019

Biotech Analysis Central Pharma News: Evoke's Mishap, ImmunoGen's Struggle, Eli Lilly's Priority Review

12:00am, Friday, 08'th Mar 2019

Evoke Pharma Q4 EPS $(0.10) Misses $(0.09) Estimate

12:00am, Wednesday, 06'th Mar 2019

H.C. Wainwright Downgrades Evoke Pharma to Neutral

12:00am, Tuesday, 05'th Mar 2019

Evoke Pharma shares are trading lower after the company received a DR letter from the FDA on its Gimoti New Drug Application; the letter describes concerns in three sections of the NDA.

12:00am, Monday, 04'th Mar 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

12:00am, Sunday, 03'rd Mar 2019

Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year —…–8 ...

12:00am, Wednesday, 27'th Feb 2019

Evoke Pharma Signs Commercial And Financial Agreement For Its Lead Product Gimoti In The US Novos Growth Partners

12:00am, Monday, 07'th Jan 2019

Evoke Pharma Q3 EPS $(0.09) Misses $(0.08) Estimate

12:00am, Tuesday, 13'th Nov 2018

Generic-Drugs Stock Outlook: No Respite from Pricing Issues

12:00am, Monday, 08'th Oct 2018

Evoke Pharma Stock News

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

71 Biggest Movers From Yesterday

Evoke Pharma Reports Submission To FDA Review Letter For Gimoti New Drug Application

Biotech Analysis Central Pharma News: Evoke's Mishap, ImmunoGen's Struggle, Eli Lilly's Priority Review

Evoke Pharma Q4 EPS $(0.10) Misses $(0.09) Estimate

H.C. Wainwright Downgrades Evoke Pharma to Neutral

Evoke Pharma shares are trading lower after the company received a DR letter from the FDA on its Gimoti New Drug Application; the letter describes concerns in three sections of the NDA.

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year —…–8 ...

Evoke Pharma Signs Commercial And Financial Agreement For Its Lead Product Gimoti In The US Novos Growth Partners

Evoke Pharma Q3 EPS $(0.09) Misses $(0.08) Estimate

Generic-Drugs Stock Outlook: No Respite from Pricing Issues

3 Things In Biotech, August 18: Finally, A New First-Line Treatment For Liver Cancer

Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA

Top Fintech Company